

# Robert D Schreiber

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/627423/robert-d-schreiber-publications-by-year.pdf>

**Version:** 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

231 papers	70,058 citations	113 h-index	246 g-index
246 ext. papers	78,229 ext. citations	16.2 avg, IF	7.87 L-index

#	Paper	IF	Citations
231	Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2021</b> , 118,	11.5	20
230	A pilot trial of neoantigen DNA vaccine in combination with nivolumab/ipilimumab and prostatic metastatic hormone-sensitive prostate cancer (mHSPC).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, TPS192-TPS192 <sup>4</sup>	22.2	19
229	An Important Role for CD4 T Cells in Adaptive Immunity to <i>Toxoplasma gondii</i> in Mice Lacking the Transcription Factor Batf3. <i>MSphere</i> , <b>2020</b> , 5,	5	3
228	Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction. <i>Cell</i> , <b>2020</b> , 183, 818-834.e13	56.2	105
227	TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy. <i>Cell</i> , <b>2020</b> , 182, 886-900.e17	56.2	95
226	cDC1 prime and are licensed by CD4 T cells to induce anti-tumour immunity. <i>Nature</i> , <b>2020</b> , 584, 624-629	50.4	94
225	Detection of neoantigen-specific T cells following a personalized vaccine in a patient with glioblastoma. <i>Onc Immunology</i> , <b>2019</b> , 8, e1561106	7.2	32
224	MHC-II neoantigens shape tumour immunity and response to immunotherapy. <i>Nature</i> , <b>2019</b> , 574, 696-704	50.4	272
223	Interferon $\gamma$ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity. <i>Cold Spring Harbor Perspectives in Biology</i> , <b>2019</b> , 11,	10.2	138
222	Cancer immunogenomic approach to neoantigen discovery in a checkpoint blockade responsive murine model of oral cavity squamous cell carcinoma. <i>Oncotarget</i> , <b>2018</b> , 9, 4109-4119	3.3	19
221	WDFY4 is required for cross-presentation in response to viral and tumor antigens. <i>Science</i> , <b>2018</b> , 362, 694-699	33.3	115
220	High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy. <i>Cell</i> , <b>2018</b> , 175, 1014-1030.e19	56.2	150
219	Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape. <i>Cancer Immunology Research</i> , <b>2017</b> , 5, 106-117	12.5	162
218	Inflammatory monocytes require type I interferon receptor signaling to activate NK cells via IL-18 during a mucosal viral infection. <i>Journal of Experimental Medicine</i> , <b>2017</b> , 214, 1153-1167	16.6	49
217	Endogenous Neoantigen-Specific CD8 T Cells Identified in Two Glioblastoma Models Using a Cancer Immunogenomics Approach. <i>Cancer Immunology Research</i> , <b>2016</b> , 4, 1007-1015	12.5	58
216	The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer. <i>Advances in Immunology</i> , <b>2016</b> , 130, 25-74	5.6	119
215	Novel ER $\alpha$ -positive breast cancer model with estrogen independent growth in the bone microenvironment. <i>Oncotarget</i> , <b>2016</b> , 7, 49751-49764	3.3	5

214	Cancer Immunosurveillance: Immunoediting <b>2016</b> , 396-405		3
213	Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop. <i>Onc Immunology</i> , <b>2016</b> , 5, e1186323	7.2	2
212	Response to interferons and antibacterial innate immunity in the absence of tyrosine-phosphorylated STAT1. <i>EMBO Reports</i> , <b>2016</b> , 17, 367-82	6.5	33
211	Novel non-canonical role of STAT1 in Natural Killer cell cytotoxicity. <i>Onc Immunology</i> , <b>2016</b> , 5, e1186314	7.2	10
210	NKG2D-NKG2D Ligand Interaction Inhibits the Outgrowth of Naturally Arising Low-Grade B Cell Lymphoma In Vivo. <i>Journal of Immunology</i> , <b>2016</b> , 196, 4805-13	5.3	14
209	Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. <i>Nature Genetics</i> , <b>2016</b> , 48, 607-16	36.3	613
208	Truncating Prolactin Receptor Mutations Promote Tumor Growth in Murine Estrogen Receptor-Alpha Mammary Carcinomas. <i>Cell Reports</i> , <b>2016</b> , 17, 249-260	10.6	14
207	Neoantigens in cancer immunotherapy. <i>Science</i> , <b>2015</b> , 348, 69-74	33.3	2790
206	Blockade of interferon Beta, but not interferon alpha, signaling controls persistent viral infection. <i>Cell Host and Microbe</i> , <b>2015</b> , 17, 653-61	23.4	114
205	CANCER. The odds of immunotherapy success. <i>Science</i> , <b>2015</b> , 350, 158-9	33.3	70
204	Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. <i>Cell</i> , <b>2015</b> , 162, 1229-41	56.2	1457
203	Tumor neoantigens: building a framework for personalized cancer immunotherapy. <i>Journal of Clinical Investigation</i> , <b>2015</b> , 125, 3413-21	15.9	370
202	Selective Blockade of Interferon- $\beta$ and - $\gamma$ Reveals Their Non-Redundant Functions in a Mouse Model of West Nile Virus Infection. <i>PLoS ONE</i> , <b>2015</b> , 10, e0128636	3.7	34
201	Abnormal Mammary Development in 129:STAT1-Null Mice is Stroma-Dependent. <i>PLoS ONE</i> , <b>2015</b> , 10, e0129895	3.7	8
200	Dual Requirement of Cytokine and Activation Receptor Triggering for Cytotoxic Control of Murine Cytomegalovirus by NK Cells. <i>PLoS Pathogens</i> , <b>2015</b> , 11, e1005323	7.6	25
199	Consensus nomenclature for CD8 T cell phenotypes in cancer. <i>Onc Immunology</i> , <b>2015</b> , 4, e998538	7.2	101
198	New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. <i>Current Opinion in Immunology</i> , <b>2014</b> , 27, 16-25	7.8	882
197	Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. <i>Nature Medicine</i> , <b>2014</b> , 20, 1301-9	50.5	596

196	Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. <i>Nature</i> , <b>2014</b> , 515, 577-81	50.4	1331
195	Dysregulated STAT1-SOCS1 control of JAK2 promotes mammary luminal progenitor cell survival and drives ER(+) tumorigenesis. <i>Cell Death and Differentiation</i> , <b>2014</b> , 21, 234-46	12.7	31
194	Persistent LCMV infection is controlled by blockade of type I interferon signaling. <i>Science</i> , <b>2013</b> , 340, 207-11	33.3	527
193	Programmable nanoparticle functionalization for in vivo targeting. <i>FASEB Journal</i> , <b>2013</b> , 27, 255-64	0.9	50
192	Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy. <i>Annals of the New York Academy of Sciences</i> , <b>2013</b> , 1284, 1-5	6.5	207
191	Identifying the initiating events of anti-Listeria responses using mice with conditional loss of IFN- $\gamma$ receptor subunit 1 (IFNGR1). <i>Journal of Immunology</i> , <b>2013</b> , 191, 4223-34	5.3	29
190	Loss of DAP12 and FcR $\gamma$ drives exaggerated IL-12 production and CD8(+) T cell response by CCR2(+) Mo-DCs. <i>PLoS ONE</i> , <b>2013</b> , 8, e76145	3.7	5
189	Anti-IFN- $\gamma$ receptor antibody treatment ameliorates disease in lupus-predisposed mice. <i>Journal of Immunology</i> , <b>2012</b> , 189, 5976-84	5.3	82
188	STAT1-deficient mice spontaneously develop estrogen receptor $\beta$ -positive luminal mammary carcinomas. <i>Breast Cancer Research</i> , <b>2012</b> , 14, R16	8.3	122
187	Compensatory dendritic cell development mediated by BATF-IRF interactions. <i>Nature</i> , <b>2012</b> , 490, 502-7	50.4	293
186	Timing and magnitude of type I interferon responses by distinct sensors impact CD8 T cell exhaustion and chronic viral infection. <i>Cell Host and Microbe</i> , <b>2012</b> , 11, 631-42	23.4	113
185	Cancer immunoediting by the innate immune system in the absence of adaptive immunity. <i>Journal of Experimental Medicine</i> , <b>2012</b> , 209, 1869-82	16.6	221
184	A dual function of NKG2D ligands in NK-cell activation. <i>European Journal of Immunology</i> , <b>2012</b> , 42, 2452-8	8.1	9
183	Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. <i>Nature</i> , <b>2012</b> , 482, 400-4	50.4	849
182	Strain-specific variation in murine natural killer gene complex contributes to differences in immunosurveillance for urethane-induced lung cancer. <i>Cancer Research</i> , <b>2012</b> , 72, 4311-7	10.1	22
181	Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state. <i>Cancer Research</i> , <b>2012</b> , 72, 3987-96	10.1	76
180	Critical role for interferon regulatory factor 3 (IRF-3) and IRF-7 in type I interferon-mediated control of murine norovirus replication. <i>Journal of Virology</i> , <b>2012</b> , 86, 13515-23	6.6	64
179	Small-animal PET of steroid hormone receptors predicts tumor response to endocrine therapy using a preclinical model of breast cancer. <i>Journal of Nuclear Medicine</i> , <b>2012</b> , 53, 1119-26	8.9	57

178	Abstract 526: Cancer immunoediting by the innate immune system in the absence of adaptive immunity <b>2012</b> ,		2
177	Type I interferon is selectively required by dendritic cells for immune rejection of tumors. <i>Journal of Experimental Medicine</i> , <b>2011</b> , 208, 1989-2003	16.6	676
176	CD8(+) dendritic cells are an obligate cellular entry point for productive infection by <i>Listeria monocytogenes</i> . <i>Immunity</i> , <b>2011</b> , 35, 236-48	32.3	140
175	Natural innate and adaptive immunity to cancer. <i>Annual Review of Immunology</i> , <b>2011</b> , 29, 235-71	34.7	1353
174	Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. <i>Science</i> , <b>2011</b> , 331, 1565-70	33.3	3816
173	CXCR3 enhances a T-cell-dependent epidermal proliferative response and promotes skin tumorigenesis. <i>Cancer Research</i> , <b>2011</b> , 71, 5707-16	10.1	32
172	Type I interferon negatively controls plasmacytoid dendritic cell numbers in vivo. <i>Journal of Experimental Medicine</i> , <b>2011</b> , 208, 2367-74	16.6	124
171	Cancer immunoediting of the NK group 2D ligand H60a. <i>Journal of Immunology</i> , <b>2011</b> , 187, 3538-45	5.3	23
170	A temporal role of type I interferon signaling in CD8+ T cell maturation during acute West Nile virus infection. <i>PLoS Pathogens</i> , <b>2011</b> , 7, e1002407	7.6	84
169	Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands. <i>Cancer Research</i> , <b>2010</b> , 70, 490-500	10.1	87
168	TAK1 targeting by glucocorticoids determines JNK and I $\kappa$ B regulation in Toll-like receptor-stimulated macrophages. <i>Blood</i> , <b>2010</b> , 115, 1921-31	2.2	44
167	Distinct and complementary functions of MDA5 and TLR3 in poly(I:C)-mediated activation of mouse NK cells. <i>Journal of Experimental Medicine</i> , <b>2009</b> , 206, 2967-76	16.6	162
166	Interleukin 12 stimulates IFN- $\gamma$ -mediated inhibition of tumor-induced regulatory T-cell proliferation and enhances tumor clearance. <i>Cancer Research</i> , <b>2009</b> , 69, 8700-9	10.1	53
165	A novel role for Stat1 in phagosome acidification and natural host resistance to intracellular infection by <i>Leishmania major</i> . <i>PLoS Pathogens</i> , <b>2009</b> , 5, e1000381	7.6	25
164	The lymphotoxin LT $\alpha$ (1) $\beta$ (2) controls postnatal and adult spleen marginal sinus vascular structure and function. <i>Immunity</i> , <b>2009</b> , 30, 408-20	32.3	35
163	DNA double-strand breaks activate a multi-functional genetic program in developing lymphocytes. <i>Nature</i> , <b>2008</b> , 456, 819-23	50.4	115
162	Immune-mediated dormancy: an equilibrium with cancer. <i>Journal of Leukocyte Biology</i> , <b>2008</b> , 84, 988-93	6.5	205
161	A critical role for type I IFN in arthritis development following <i>Borrelia burgdorferi</i> infection of mice. <i>Journal of Immunology</i> , <b>2008</b> , 181, 8492-503	5.3	62

160	Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2008</b> , 105, 652-6	11.5	246
159	Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. <i>Science</i> , <b>2008</b> , 322, 1097-100	33.3	1285
158	HIF-1alpha regulates epithelial inflammation by cell autonomous NFkappaB activation and paracrine stromal remodeling. <i>Blood</i> , <b>2008</b> , 111, 3343-54	2.2	114
157	Prolongation of cardiac and islet allograft survival by a blocking hamster anti-mouse CXCR3 monoclonal antibody. <i>Transplantation</i> , <b>2008</b> , 86, 137-47	1.8	58
156	IL-12 Stimulates Interferon-Gamma Mediated Inhibition of Tumor-Induced Regulatory T Cell Proliferation and Enhances Tumor Clearance. <i>Blood</i> , <b>2008</b> , 112, 2558-2558	2.2	1
155	Adaptive immunity maintains occult cancer in an equilibrium state. <i>Nature</i> , <b>2007</b> , 450, 903-7	50.4	999
154	Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. <i>Journal of Immunology</i> , <b>2007</b> , 178, 7540-9	5.3	216
153	ABIN-3: a molecular basis for species divergence in interleukin-10-induced anti-inflammatory actions. <i>Molecular and Cellular Biology</i> , <b>2007</b> , 27, 4603-16	4.8	45
152	A novel c-Jun-dependent signal transduction pathway necessary for the transcriptional activation of interferon gamma response genes. <i>Journal of Biological Chemistry</i> , <b>2007</b> , 282, 938-46	5.4	44
151	Vav proteins control MyD88-dependent oxidative burst. <i>Blood</i> , <b>2007</b> , 109, 3360-8	2.2	67
150	Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes?. <i>Current Opinion in Immunology</i> , <b>2007</b> , 19, 203-8	7.8	232
149	Novel STAT1 alleles in otherwise healthy patients with mycobacterial disease. <i>PLoS Genetics</i> , <b>2006</b> , 2, e131	6	138
148	Comparative analysis of regulatory and effector T cells in progressively growing versus rejecting tumors of similar origins. <i>Cancer Research</i> , <b>2006</b> , 66, 7301-9	10.1	87
147	NF-kappa B-inducing kinase regulates selected gene expression in the Nod2 signaling pathway. <i>Infection and Immunity</i> , <b>2006</b> , 74, 2121-7	3.7	44
146	IFN-dependent down-regulation of the NKG2D ligand H60 on tumors. <i>Journal of Immunology</i> , <b>2006</b> , 176, 905-13	5.3	85
145	Bone marrow stromal cell antigen 2 is a specific marker of type I IFN-producing cells in the naive mouse, but a promiscuous cell surface antigen following IFN stimulation. <i>Journal of Immunology</i> , <b>2006</b> , 177, 3260-5	5.3	342
144	Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. <i>Advances in Immunology</i> , <b>2006</b> , 90, 1-50	5.6	568
143	Blocking monoclonal antibodies specific for mouse IFN-alpha/beta receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic transfection. <i>Journal of Interferon and Cytokine Research</i> , <b>2006</b> , 26, 804-19	3.5	197

142	Perforin and granzymes have distinct roles in defensive immunity and immunopathology. <i>Immunity</i> , <b>2006</b> , 25, 835-48	32.3	122
141	Suppressor of cytokine signaling 1 regulates the immune response to infection by a unique inhibition of type I interferon activity. <i>Nature Immunology</i> , <b>2006</b> , 7, 33-9	19.1	218
140	Interferons, immunity and cancer immunoediting. <i>Nature Reviews Immunology</i> , <b>2006</b> , 6, 836-48	36.5	1091
139	IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. <i>Cancer Research</i> , <b>2005</b> , 65, 3447-53	10.1	130
138	Interferon-gamma and cancer immunoediting. <i>Immunologic Research</i> , <b>2005</b> , 32, 231-45	4.3	104
137	Gains of glycosylation comprise an unexpectedly large group of pathogenic mutations. <i>Nature Genetics</i> , <b>2005</b> , 37, 692-700	36.3	168
136	A critical function for type I interferons in cancer immunoediting. <i>Nature Immunology</i> , <b>2005</b> , 6, 722-9	19.1	435
135	IFN-gamma controls the generation/activation of CD4+ CD25+ regulatory T cells in antitumor immune response. <i>Journal of Immunology</i> , <b>2005</b> , 175, 4433-40	5.3	82
134	Definition of target antigens for naturally occurring CD4(+) CD25(+) regulatory T cells. <i>Journal of Experimental Medicine</i> , <b>2005</b> , 201, 681-6	16.6	111
133	Cancer vaccines 2004 opening address: the molecular and cellular basis of cancer immunosurveillance and immunoediting. <i>Cancer Immunity</i> , <b>2005</b> , 5 Suppl 1, 1		6
132	Response to the cancer immunosurveillance controversy. <i>Nature Immunology</i> , <b>2004</b> , 5, 4-5	19.1	16
131	A role for the immunological synapse in lineage commitment of CD4 lymphocytes. <i>Nature</i> , <b>2004</b> , 431, 527-32	50.4	157
130	The three Es of cancer immunoediting. <i>Annual Review of Immunology</i> , <b>2004</b> , 22, 329-60	34.7	1946
129	The immunobiology of cancer immunosurveillance and immunoediting. <i>Immunity</i> , <b>2004</b> , 21, 137-48	32.3	2015
128	Enhanced tumorigenesis in HTLV-1 tax-transgenic mice deficient in interferon-gamma. <i>Blood</i> , <b>2004</b> , 104, 3305-11	2.2	46
127	Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency. <i>Nature Genetics</i> , <b>2003</b> , 33, 388-91	36.3	634
126	Interferon- $\gamma$ . <i>Nature</i> , <b>2003</b> , 425, 567-601		9
125	The IkappaB function of NF-kappaB2 p100 controls stimulated osteoclastogenesis. <i>Journal of Experimental Medicine</i> , <b>2003</b> , 198, 771-81	16.6	234



124	Toll-like receptor-dependent production of IL-12p40 causes chronic enterocolitis in myeloid cell-specific Stat3-deficient mice. <i>Journal of Clinical Investigation</i> , <b>2003</b> , 111, 1297-308	15.9	197
123	IFN $\gamma$ Receptor-STAT1 Signaling and Cancer Immunoediting <b>2003</b> , 399-418		
122	Cancer immunoediting: from immunosurveillance to tumor escape. <i>Nature Immunology</i> , <b>2002</b> , 3, 991-8	19.1	3444
121	IFN-producing cells respond to CXCR3 ligands in the presence of CXCL12 and secrete inflammatory chemokines upon activation. <i>Journal of Immunology</i> , <b>2002</b> , 169, 6079-83	5.3	128
120	STAT1 deficiency unexpectedly and markedly exacerbates the pathophysiological actions of IFN-alpha in the central nervous system. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2002</b> , 99, 16209-14	11.5	47
119	The roles of IFN gamma in protection against tumor development and cancer immunoediting. <i>Cytokine and Growth Factor Reviews</i> , <b>2002</b> , 13, 95-109	17.9	650
118	Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. <i>Cell</i> , <b>2002</b> , 109 Suppl, S121-31	56.2	850
117	Stat1-dependent and -independent pathways in IFN-gamma-dependent signaling. <i>Trends in Immunology</i> , <b>2002</b> , 23, 96-101	14.4	477
116	A completely foreign receptor can mediate an interferon-gamma-like response. <i>EMBO Journal</i> , <b>2001</b> , 20, 5431-42	13	27
115	IFN $\gamma$ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. <i>Nature</i> , <b>2001</b> , 410, 1107-11	50.4	2020
114	Defective lymphotoxin-beta receptor-induced NF-kappaB transcriptional activity in NIK-deficient mice. <i>Science</i> , <b>2001</b> , 291, 2162-5	33.3	360
113	ERK1 and ERK2 activate CCAAT/enhancer-binding protein-beta-dependent gene transcription in response to interferon-gamma. <i>Journal of Biological Chemistry</i> , <b>2001</b> , 276, 287-97	5.4	124
112	Biologic consequences of Stat1-independent IFN signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2001</b> , 98, 6680-5	11.5	309
111	Stat1-independent regulation of gene expression in response to IFN-gamma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2001</b> , 98, 6674-9	11.5	214
110	Measurement of mouse and human interferon gamma. <i>Current Protocols in Immunology</i> , <b>2001</b> , Chapter 6, Unit 6.8	4	4
109	Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation. <i>Science</i> , <b>2001</b> , 293, 300-3	33.3	419
108	Stat-1 is not essential for inhibition of B lymphopoiesis by type I IFNs. <i>Journal of Immunology</i> , <b>2000</b> , 165, 2362-6	5.3	30
107	Partial interferon-gamma receptor signaling chain deficiency in a patient with bacille Calmette-Guérin and Mycobacterium abscessus infection. <i>Journal of Infectious Diseases</i> , <b>2000</b> , 181, 379-84		152



106	Eradication of established tumors by CD8+ T cell adoptive immunotherapy. <i>Immunity</i> , <b>2000</b> , 13, 265-76	32.3	283
105	CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1999</b> , 96, 8633-8	11.5	279
104	Interleukin-10 receptor signaling through the JAK-STAT pathway. Requirement for two distinct receptor-derived signals for anti-inflammatory action. <i>Journal of Biological Chemistry</i> , <b>1999</b> , 274, 16513-21	5.4	276
103	Reversal of virus-induced systemic shock and respiratory failure by blockade of the lymphotoxin pathway. <i>Nature Medicine</i> , <b>1999</b> , 5, 1370-4	50.5	55
102	A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection. <i>Nature Genetics</i> , <b>1999</b> , 21, 370-8	36.3	402
101	Baculovirus stimulates antiviral effects in mammalian cells. <i>Journal of Virology</i> , <b>1999</b> , 73, 9944-51	6.6	114
100	Type I interferons are essential mediators of apoptotic death in virally infected cells. <i>Genes To Cells</i> , <b>1998</b> , 3, 29-37	2.3	135
99	Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. <i>Cell</i> , <b>1998</b> , 93, 373-83	56.2	675
98	How cells respond to interferons. <i>Annual Review of Biochemistry</i> , <b>1998</b> , 67, 227-64	29.1	3365
97	A causative relationship between mutant IFNGR1 alleles and impaired cellular response to IFNgamma in a compound heterozygous child. <i>American Journal of Human Genetics</i> , <b>1998</b> , 62, 723-6	11	90
96	Functional cooperation of the interleukin-2 receptor beta chain and Jak1 in phosphatidylinositol 3-kinase recruitment and phosphorylation. <i>Molecular and Cellular Biology</i> , <b>1998</b> , 18, 6416-22	4.8	46
95	Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1998</b> , 95, 7556-61	11.5	1126
94	IFN-gamma action on pancreatic beta cells causes class I MHC upregulation but not diabetes. <i>Journal of Clinical Investigation</i> , <b>1998</b> , 102, 1249-57	15.9	100
93	Synergy between interferon-gamma and tumor necrosis factor-alpha in transcriptional activation is mediated by cooperation between signal transducer and activator of transcription 1 and nuclear factor kappaB. <i>Journal of Biological Chemistry</i> , <b>1997</b> , 272, 14899-907	5.4	332
92	Ligand-induced formation of p55 and p75 tumor necrosis factor receptor heterocomplexes on intact cells. <i>Journal of Biological Chemistry</i> , <b>1997</b> , 272, 10784-9	5.4	65
91	The molecular basis of IFN action. <i>Growth Factors and Cytokines in Health and Disease</i> , <b>1997</b> , 521-556		1
90	Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. <i>Journal of Experimental Medicine</i> , <b>1997</b> , 185, 1573-84	16.6	257
89	The IFN gamma receptor: a paradigm for cytokine receptor signaling. <i>Annual Review of Immunology</i> , <b>1997</b> , 15, 563-91	34.7	856

88	Partial interferon-gamma receptor 1 deficiency in a child with tuberculoid bacillus Calmette-Guérin infection and a sibling with clinical tuberculosis. <i>Journal of Clinical Investigation</i> , <b>1997</b> , 100, 2658-64	15.9	279
87	Stat3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain. <i>Journal of Biological Chemistry</i> , <b>1996</b> , 271, 27954-61	5.4	171
86	Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. <i>Cell</i> , <b>1996</b> , 84, 431-42	56.2	1428
85	Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. <i>Immunity</i> , <b>1996</b> , 4, 25-36	32.3	947
84	Identification of an interferon-gamma receptor alpha chain sequence required for JAK-1 binding. <i>Journal of Biological Chemistry</i> , <b>1996</b> , 271, 9-12	5.4	77
83	Ligand-induced assembly and activation of the gamma interferon receptor in intact cells. <i>Molecular and Cellular Biology</i> , <b>1996</b> , 16, 3214-21	4.8	117
82	Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1996</b> , 93, 7673-8	11.5	426
81	Phosphorylated interferon-alpha receptor 1 subunit (IFN $\alpha$ R1) acts as a docking site for the latent form of the 113 kDa STAT2 protein.. <i>EMBO Journal</i> , <b>1996</b> , 15, 1064-1074	13	138
80	Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. <i>European Journal of Immunology</i> , <b>1996</b> , 26, 1335-41	6.1	122
79	Regulation of IFN-alpha/beta genes: evidence for a dual function of the transcription factor complex ISGF3 in the production and action of IFN-alpha/beta. <i>Genes To Cells</i> , <b>1996</b> , 1, 995-1005	2.3	83
78	Interleukin 12 signaling in T helper type 1 (Th1) cells involves tyrosine phosphorylation of signal transducer and activator of transcription (Stat)3 and Stat4. <i>Journal of Experimental Medicine</i> , <b>1995</b> , 181, 1755-62	16.6	574
77	Response and resistance to interferons and interacting cytokines. <i>Journal of the National Cancer Institute</i> , <b>1995</b> , 87, 257-64	9.7	9
76	Monoclonal antibodies specific for murine p55 and p75 tumor necrosis factor receptors: identification of a novel in vivo role for p75. <i>Journal of Experimental Medicine</i> , <b>1995</b> , 181, 607-17	16.6	142
75	Stat recruitment by tyrosine-phosphorylated cytokine receptors: an ordered reversible affinity-driven process. <i>Immunity</i> , <b>1995</b> , 2, 677-87	32.3	251
74	Tissue-specific targeting of cytokine unresponsiveness in transgenic mice. <i>Immunity</i> , <b>1995</b> , 3, 657-66	32.3	81
73	Ligand-induced autoregulation of IFN-gamma receptor beta chain expression in T helper cell subsets. <i>Science</i> , <b>1995</b> , 270, 1215-8	33.3	177
72	Interferon gamma signals via a high-affinity multisubunit receptor complex that contains two types of polypeptide chain. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1995</b> , 92, 5401-5	11.5	83
71	Ligand-induced IFN gamma receptor tyrosine phosphorylation couples the receptor to its signal transduction system (p91).. <i>EMBO Journal</i> , <b>1994</b> , 13, 1591-1600	13	310

70	In vitro megakaryocytopoietic and thrombopoietic activity of c-mpl ligand (TPO) on purified murine hematopoietic stem cells. <i>Blood</i> , <b>1994</b> , 84, 4045-4052	2.2	214
69	Effect of tumor necrosis factor alpha on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process. <i>Journal of Experimental Medicine</i> , <b>1994</b> , 180, 995-1004	16.6	281
68	Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. <i>Nature</i> , <b>1994</b> , 372, 560-3	50.4	533
67	Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. <i>Immunity</i> , <b>1994</b> , 1, 447-56	32.3	464
66	Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1994</b> , 91, 3764-8	11.5	360
65	Anti-tumor necrosis factor modulates anti-CD3-triggered T cell cytokine gene expression in vivo. <i>Journal of Clinical Investigation</i> , <b>1994</b> , 93, 2189-96	15.9	67
64	IFN-gamma produced in vivo during the first two days is critical for resolution of murine Leishmania major infections. <i>Microbial Pathogenesis</i> , <b>1993</b> , 14, 495-500	3.8	12
63	The molecular cell biology of interferon-gamma and its receptor. <i>Annual Review of Immunology</i> , <b>1993</b> , 11, 571-611	34.7	1136
62	Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis. <i>Journal of Experimental Medicine</i> , <b>1993</b> , 178, 1541-54	16.6	414
61	The biology and biochemistry of interferon-gamma and its receptor. <i>Gastroenterologia Japonica</i> , <b>1993</b> , 28 Suppl 4, 88-94; discussion 95-6		17
60	Tumor necrosis factor-alpha prevents rejection of islet xenografts (rat to mouse). <i>Diabetes</i> , <b>1993</b> , 42, 651-657	0.9	3
59	Monoclonal anti-tumor necrosis factor antibody renders non-obese diabetic mice hypersensitive to irradiation and enhances insulinitis development. <i>International Immunology</i> , <b>1992</b> , 4, 611-4	4.9	41
58	Interleukin 1 participates in the development of anti-Listeria responses in normal and SCID mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1992</b> , 89, 1011-5	11.5	90
57	Identification of a functionally important sequence in the C terminus of the interferon-gamma receptor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1992</b> , 89, 11706-10	11.5	98
56	CD8 T cells can protect against an intracellular bacterium in an interferon gamma-independent fashion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1992</b> , 89, 11612-6	11.5	108
55	The structure and function of interferon-gamma receptors. <i>International Journal of Immunopharmacology</i> , <b>1992</b> , 14, 413-9		14
54	HBsAg retention sensitizes the hepatocyte to injury by physiological concentrations of interferon-gamma. <i>Hepatology</i> , <b>1992</b> , 16, 655-63	11.2	130
53	Natural immunity: a T-cell-independent pathway of macrophage activation, defined in the scid mouse. <i>Immunological Reviews</i> , <b>1991</b> , 124, 5-24	11.3	271

52	Role of cytokines (interleukin 1, tumor necrosis factor, and transforming growth factor beta) in natural and lipopolysaccharide-enhanced radioresistance. <i>Journal of Experimental Medicine</i> , <b>1991</b> , 173, 1177-82	16.6	97
51	Characterization and expression of the human leukocyte-common antigen (CD45) gene contained in yeast artificial chromosomes. <i>Genomics</i> , <b>1991</b> , 10, 756-64	4.3	16
50	Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. <i>Nature</i> , <b>1990</b> , 348, 334-6	50.4	3318
49	Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation. <i>European Journal of Immunology</i> , <b>1990</b> , 20, 509-15	6.1	227
48	Transforming growth factor beta decreases the immunogenicity of rat islet xenografts (rat to mouse) and prevents rejection in association with treatment of the recipient with a monoclonal antibody to interferon gamma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1990</b> , 87, 1591-5	11.5	34
47	Gamma interferon limits access of <i>Listeria monocytogenes</i> to the macrophage cytoplasm. <i>Journal of Experimental Medicine</i> , <b>1989</b> , 170, 2141-6	16.6	174
46	Enumeration of cytokine-secreting cells at the single-cell level. <i>European Journal of Immunology</i> , <b>1989</b> , 19, 1591-7	6.1	24
45	Prevention of the graft-versus-host reaction in newborn mice by antibodies to tumor necrosis factor-alpha. <i>Transplantation</i> , <b>1989</b> , 47, 1057-61	1.8	55
44	Cloning and expression of the cDNA for the murine interferon gamma receptor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1989</b> , 86, 8497-501	11.5	93
43	Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection. Experimental visceral leishmaniasis. <i>Journal of Clinical Investigation</i> , <b>1989</b> , 83, 1253-7	15.9	103
42	Interferon-gamma: the major mediator of resistance against <i>Toxoplasma gondii</i> . <i>Science</i> , <b>1988</b> , 240, 516-8	35.3	940
41	Up-regulation of gamma interferon receptors on the human monocytic cell line U937 by 1,25-dihydroxyvitamin D3 and granulocyte-macrophage colony stimulating factor. <i>Journal of Leukocyte Biology</i> , <b>1988</b> , 44, 187-91	6.5	18
40	Purification and characterization of the human interferon-gamma receptor from placenta. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1988</b> , 85, 4837-41	11.5	66
39	Opsonization of bacteroides by the alternative complement pathway reconstructed from isolated plasma proteins. <i>Journal of Experimental Medicine</i> , <b>1987</b> , 165, 777-98	16.6	12
38	Hypocomplementemic glomerulonephritis in an infant and mother. Evidence for an abnormal form of C3. <i>American Journal of Nephrology</i> , <b>1987</b> , 7, 470-7	4.6	21
37	Macrophage activation factor from EL-4, a murine T-cell line: antigenic characterization by hamster monoclonal antibodies to murine interferon-gamma. <i>Cellular Immunology</i> , <b>1987</b> , 107, 340-7	4.4	3
36	Deficiency of erythrocyte C3b receptor (CR1) in AIDS and AIDS-related syndromes. <i>Bioscience Reports</i> , <b>1986</b> , 6, 81-6	4.1	9
35	Altered erythrocyte C3b receptor expression, immune complexes, and complement activation in homosexual men in varying risk groups for acquired immune deficiency syndrome. <i>Journal of Clinical Investigation</i> , <b>1986</b> , 78, 977-82	15.9	102

34	Requirement of endogenous interferon-gamma production for resolution of <i>Listeria monocytogenes</i> infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1985</b> , 82, 7404-8	11.5	452
33	Leprosy: altered complement receptors in disseminated disease. <i>Journal of Investigative Dermatology</i> , <b>1985</b> , 85, 58s-61s	4.3	19
32	Rapid induction of the expression of proto-oncogene fos during human monocytic differentiation. <i>Cell</i> , <b>1985</b> , 40, 209-17	56.2	380
31	Demonstration and partial characterization of the interferon-gamma receptor on human mononuclear phagocytes. <i>Journal of Clinical Investigation</i> , <b>1985</b> , 76, 2196-205	15.9	76
30	The Chemistry and Biology of Complement Receptors <b>1985</b> , 115-143		3
29	Evidence for a gamma-interferon receptor that regulates macrophage tumoricidal activity. <i>Journal of Experimental Medicine</i> , <b>1984</b> , 160, 55-74	16.6	405
28	Macrophage I-A/I-E expression and macrophage-stimulating lymphokines in murine lupus. <i>Cellular Immunology</i> , <b>1984</b> , 87, 92-100	4.4	33
27	Enumeration and characterization of human killer and natural killer cells by a modified single-cell assay. <i>Scandinavian Journal of Immunology</i> , <b>1984</b> , 19, 529-39	3.4	13
26	The chemistry and biology of complement receptors. <i>Seminars in Immunopathology</i> , <b>1984</b> , 7, 221-49		51
25	Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum. <i>Journal of Clinical Investigation</i> , <b>1984</b> , 73, 160-70	15.9	46
24	Paroxysmal nocturnal hemoglobinuria: deficiency in factor H-like functions of the abnormal erythrocytes. <i>Journal of Experimental Medicine</i> , <b>1983</b> , 157, 1971-80	16.6	86
23	Macrophage activation: priming activity from a T-cell hybridoma is attributable to interferon-gamma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1983</b> , 80, 3782-6	11.5	138
22	Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1983</b> , 80, 5430-4	11.5	253
21	Identification of a T cell hybridoma that produces large quantities of macrophage-activating factor. <i>Journal of Experimental Medicine</i> , <b>1982</b> , 156, 677-89	16.6	50
20	Anti-Mac-1 selectively inhibits the mouse and human type three complement receptor. <i>Journal of Experimental Medicine</i> , <b>1982</b> , 156, 1000-9	16.6	527
19	The role of C3 fragments in endocytosis and extracellular cytotoxic reactions by polymorphonuclear leukocytes. <i>Clinical Immunology and Immunopathology</i> , <b>1982</b> , 23, 335-57		55
18	The role of antibody and complement in lysing virus-infected cells. <i>Medical Microbiology and Immunology</i> , <b>1982</b> , 170, 221-7	4	4
17	C3 modified at the thiolester site: acquisition of reactivity with cellular C3b receptors. <i>Bioscience Reports</i> , <b>1981</b> , 1, 873-80	4.1	22

16	Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3. <i>Journal of Experimental Medicine</i> , <b>1981</b> , 154, 856-67	16.6	365
15	Interaction of target cell-bound C3bi and C3d with human lymphocyte receptors. Enhancement of antibody-mediated cellular cytotoxicity. <i>Journal of Experimental Medicine</i> , <b>1981</b> , 153, 1592-603	16.6	98
14	Molecular biology and chemistry of the alternative pathway of complement. <i>Advances in Immunology</i> , <b>1980</b> , 29, 1-53	5.6	343
13	Antibody-independent activation of the alternative complement pathway by measles virus-infected cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1980</b> , 77, 559-62	11.5	88
12	Identification of the activator system for antibody to Toxoplasma as the classical complement pathway. <i>Journal of Infectious Diseases</i> , <b>1980</b> , 141, 366-9	7	48
11	Raji cell injury and subsequent lysis by the purified cytolytic alternative pathway of human complement. <i>Clinical Immunology and Immunopathology</i> , <b>1980</b> , 15, 384-96		59
10	Lysis of measles virus-infected cells by the purified cytolytic alternative complement pathway and antibody. <i>Journal of Experimental Medicine</i> , <b>1979</b> , 150, 445-54	16.6	66
9	Bactericidal activity of the alternative complement pathway generated from 11 isolated plasma proteins. <i>Journal of Experimental Medicine</i> , <b>1979</b> , 149, 870-82	16.6	145
8	Assembly of the cytolytic alternative pathway of complement from 11 isolated plasma proteins. <i>Journal of Experimental Medicine</i> , <b>1978</b> , 148, 1722-7	16.6	57
7	Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1978</b> , 75, 3948-52	11.5	141
6	Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. <i>Journal of Experimental Medicine</i> , <b>1977</b> , 146, 257-70	16.6	641
5	Alternative pathway of complement: demonstration and characterization of initiating factor and its properdin-independent function. <i>Journal of Experimental Medicine</i> , <b>1976</b> , 144, 1062-75	16.6	54
4	A molecular concept of the properdin pathway. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1976</b> , 73, 612-6	11.5	84
3	Properdin- and nephritic factor-dependent C3 convertases: requirement of native C3 for enzyme formation and the function of bound C3b as properdin receptor. <i>Journal of Experimental Medicine</i> , <b>1975</b> , 142, 760-72	16.6	98
2	Fourth component of human complement: description of a three polypeptide chain structure. <i>Journal of Experimental Medicine</i> , <b>1974</b> , 140, 1324-35	16.6	174
1	BCL6-dependent TCF-1+ progenitor cells maintain effector and helper CD4 T cell responses to persistent antigen		1